Related Experiment Videos

The effect of nebivolol on P wave duration and dispersion in patients with Behçet's disease; a prospective single-arm

Hasan Akkaya1, Mustafa Serkan Karakaş, Omer Sahin

  • 1Clinic of Cardiology, Niğde State Hospital, Niğde-Turkey. mserkan19@hotmail.com.

Anadolu Kardiyoloji Dergisi : AKD = the Anatolian Journal of Cardiology
|September 3, 2013
PubMed

Insights

Nebivolol significantly reduced P wave dispersion in Behçet's disease (BD) patients. This study shows nebivolol's potential to improve cardiac electrical activity in BD.

Area of Science:

  • Cardiology
  • Pharmacology
  • Rheumatology

Background:

  • Behçet's disease (BD) is a multisystem disorder linked to cardiac issues like diastolic dysfunction and arrhythmia.
  • P wave dispersion (PD) indicates irregular sinus impulse propagation and is often prolonged in BD patients.

Purpose of the Study:

  • To investigate the efficacy of nebivolol in reducing P wave duration and dispersion in patients with Behçet's disease.

Main Methods:

  • A prospective, single-arm study involving 35 BD patients diagnosed by International Study Group criteria.
  • Patients received 5 mg of nebivolol daily for 3 months, with electrocardiography performed at baseline and after therapy.
  • P wave dispersion (PD) was calculated as the difference between maximum and minimum P wave durations.

Main Results:

  • Nebivolol treatment resulted in a significant reduction in PD (62.85±21.62 to 44.28±18.03 msec, p=0.001).
  • No adverse effects were reported during the 3-month treatment period.

Conclusions:

  • Behçet's disease is associated with prolonged P wave duration and dispersion.
  • Nebivolol demonstrated a significant decrease in P wave duration and PD in BD patients, marking a novel finding.
  • Further research is warranted to ascertain the long-term cardiovascular benefits of nebivolol in BD.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...